Please select the option that best describes you:
Given the HELEN-006 trial results, under what circumstances, if any, would you consider de-escalated neoadjuvant therapy in HER2-positive breast cancer?
In this recently published phase 3 randomized controlled trial, neoadjuvant abraxane/trastuzumab/pertuzumab x6 cycles appear to compare favorably with TCHP. Would you consider this data practice changing; if so, in which patients would you consider de-escalated therapy?
Answer from: Medical Oncologist at Academic Institution
The phase III HELEN-006 trial of abraxane/trastuzumab/pertuzumab (AHP) vs TCHP was first presented with positive results at SABCS 2023, then at AACR 2024, and finally published fully in January 2025 in the Lancet. To summarize the findings, the Lancet 2025 article documented that in this randomized ...
Sign in or Register to read more